OncoGuide OncoScreen Plus CDx System
Japan-approved NGS companion diagnostic system for PIK3CA, AKT1 and PTEN alterations in defined breast cancer treatment selection.
- Developer
- Riken Genesis
- Intended use
- Other
- Cancer scope
- Breast cancer
- Specimen
- FFPE tumor tissue
- Molecular modality
- DNA mutation
- Current version
- Current OncoGuide OncoScreen Plus CDx System (2026-09)
- Evidence context
- 0 structured studies · 0 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.